Medical Therapy of Thoracic Aortic Aneurysms

Trends in Cardiovascular Medicine

Volumn 22, Issue 7, 2012, Pages 180-184

  Danyi, Peter ^a   Elefteriades, John A ^b   Jovin, Ion S ^b,c,d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b YALE UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CD18 ANTIBODY; CHYMASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXYCYCLINE; GELATINASE B; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOMETACIN; LOSARTAN; MACROLIDE; MONOCLONAL ANTIBODY; NEBIVOLOL; PERINDOPRIL; PROPRANOLOL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ROXITHROMYCIN; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TETRACYCLINE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG;

ABDOMINAL AORTA ANEURYSM; ANEURYSM DILATATION; AORTA DISSECTING ANEURYSM; AORTA RUPTURE; ARTERY DILATATION; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG MECHANISM; HUMAN; LIFESTYLE MODIFICATION; MARFAN SYNDROME; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SURGICAL RISK; THORACIC AORTA ANEURYSM;

AORTIC ANEURYSM, THORACIC; HUMANS;

EID: 84869022659     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2012.07.017     Document Type: Review

References (42)

1. Ahimastos A.A., Aggarwal A., D'Orsa K.M., et al. Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: A randomized controlled trial. JAMA 2007, 298:1539-1547.
2. Baxter B.T., Pearce W.H., Waltke E.A., et al. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: Report of a prospective (phase II) multicenter study. J Vasc Surg 2002, 36:1-12.
3. Biery N.J., Eldadah Z.A., Moore C.S., et al. Revised genomic organization of FBN1 and significance for regulated gene expression. Genomics 1999, 56:70-77.
4. Bonser R.S., Pagano D., Lewis M.E., et al. Clinical and patho-anatomical factors affecting expansion of thoracic aortic aneurysms. Heart 2000, 84:277-283.
5. Brooke B.S., Habashi J.P., Judge D.P., et al. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 2008, 358:2787-2795.
6. Coady M.A., Rizzo J.A., Goldstein L.J., Elefteriades J.A. Natural history, pathogenesis, and etiology of thoracic aortic aneurysms and dissections. Cardiol Clin 1999, 17:615-635. vii.
7. Conrad M.F., Ergul E.A., Patel V.I., et al. Management of diseases of the descending thoracic aorta in the endovascular era: A Medicare population study. Ann Surg 2010, 252:603-610.
8. Danyi P., Elefteriades J.A., Jovin I.S. Medical therapy of thoracic aortic aneurysms: Are we there yet?. Circulation 2011, 124:1469-1476.
9. Ejiri J., Inoue N., Tsukube T., et al. Oxidative stress in the pathogenesis of thoracic aortic aneurysm: Protective role of statin and angiotensin II type 1 receptor blocker. Cardiovasc Res 2003, 59:988-996.
10. Elefteriades J.A., Farkas E.A. Thoracic aortic aneurysm clinically pertinent controversies and uncertainties. J Am Coll Cardiol 2010, 55:841-857.
11. Ferguson C.D., Clancy P., Bourke B., et al. Association of statin prescription with small abdominal aortic aneurysm progression. Am Heart J 2010, 159:307-313.
12. Gadowski G.R., Pilcher D.B., Ricci M.A. Abdominal aortic aneurysm expansion rate: Effect of size and beta-adrenergic blockade. J Vasc Surg 1994, 19:727-731.
13. Gambarin F.I., Favalli V., Serio A., et al. Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations. J Cardiovasc Med (Hagerstown) 2009, 10:354-362.
14. Goel S.S., Tuzcu E.M., Agarwal S., et al. Comparison of ascending aortic size in patients with severe bicuspid aortic valve stenosis treated with versus without a statin drug. Am J Cardiol 2011, 108:1458-1462.
15. Golledge J., Muller J., Daugherty A., Norman P. Abdominal aortic aneurysm: Pathogenesis and implications for management. Arterioscler Thromb Vasc Biol 2006, 26:2605-2613.
16. Habashi J.P., Judge D.P., Holm T.M., et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006, 312:117-121.
17. Hackam D.G., Thiruchelvam D., Redelmeier D.A. Angiotensin-converting enzyme inhibitors and aortic rupture: A population-based case-control study. Lancet 2006, 368:659-665.
18. Heinemann M., Laas J., Karck M., Borst H.G. Thoracic aortic aneurysms after acute type A aortic dissection: Necessity for follow-up. Ann Thorac Surg 1990, 49:580-584.
19. Hiratzka L.F., Bakris G.L., Beckman J.A., et al. ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 2010, 121:e266-e369.
20. Isselbacher E.M. Thoracic and abdominal aortic aneurysms. Circulation 2005, 111:816-828.
21. Ito S., Akutsu K., Tamori Y., et al. Differences in atherosclerotic profiles between patients with thoracic and abdominal aortic aneurysms. Am J Cardiol 2008, 101:696-699.
22. Jovin I.S., Duggal M., Ebisu K., et al. Comparison of the effect on long-term outcomes in patients with thoracic aortic aneurysms of taking versus not taking a statin drug. Am J Cardiol 2012, 109:1050-1054.
23. Karthikesalingam A., Holt P.J., Hinchliffe R.J., et al. The diagnosis and management of aortic dissection. Vasc Endovasc Surg 2010, 44:165-169.
24. Kent K.C., Zwolak R.M., Jaff M.R., et al. Screening for abdominal aortic aneurysm: A consensus statement. J Vasc Surg 2004, 39:267-269.
25. Leach S.D., Toole A.L., Stern H., et al. Effect of beta-adrenergic blockade on the growth rate of abdominal aortic aneurysms. Arch Surg 1988, 123:606-609.
26. Lederle F.A., Johnson G.R., Wilson S.E., et al. Prevalence and associations of abdominal aortic aneurysm detected through screening: Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med 1997, 126:441-449.
27. Lindholt J.S., Vammen S., Juul S., et al. The validity of ultrasonographic scanning as screening method for abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 1999, 17:472-475.
28. Longo G.M., Xiong W., Greiner T.C., et al. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002, 110:625-632.
29. Moran C.S., McCann M., Karan M., et al. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation 2005, 111:3119-3125.
30. Mosorin M., Juvonen J., Biancari F., et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: A randomized, double-blind, placebo-controlled pilot study. J Vasc Surg 2001, 34:606-610.
31. Nagashima H., Uto K., Sakomura Y., et al. An angiotensin-converting enzyme inhibitor, not an angiotensin II type-1 receptor blocker, prevents beta-aminopropionitrile monofumarate-induced aortic dissection in rats. J Vasc Surg 2002, 36:818-823.
32. Nicod P., Bloor C., Godfrey M., et al. Familial aortic dissecting aneurysm. J Am Coll Cardiol 1989, 13:811-819.
33. Propranolol for small abdominal aortic aneurysms: Results of a randomized trial. J Vasc Surg 2002, 35:72-79. Propranolol Aneurysm Trial Investigators.
34. Rizzoni D., Rodella L., Porteri E., et al. Effects of losartan and enalapril at different doses on cardiac and renal interstitial matrix in spontaneously hypertensive rats. Clin Exp Hypertens 2003, 25:427-441.
35. Satoh K., Nigro P., Matoba T., et al. Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat Med 2009, 15:649-656.
36. Shores J., Berger K.R., Murphy E.A., Pyeritz R.E. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med 1994, 330:1335-1341.
37. Sukhija R., Aronow W.S., Sandhu R., et al. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol 2006, 97:279-280.
38. Sweeting M.J., Thompson S.G., Brown L.C., et al. Use of angiotensin converting enzyme inhibitors is associated with increased growth rate of abdominal aortic aneurysms. J Vasc Surg 2010, 52:1-4.
39. Vammen S., Lindholt J.S., Ostergaard L., et al. Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion. Br J Surg 2001, 88:1066-1072.
40. Yoshimura K., Aoki H., Ikeda Y., et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med 2005, 11:1330-1338.
41. Yu H.Y., Chen Y.S., Huang S.C., et al. Late outcome of patients with aortic dissection: Study of a national database. Eur J Cardiothorac Surg 2004, 25:683-690.
42. Zhang Y., Naggar J.C., Welzig C.M., et al. Simvastatin inhibits angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-knockout mice: Possible role of ERK. Arterioscler Thromb Vasc Biol 2009, 29:1764-1771.